Teva Wins $176M From Eli Lilly In Migraine Drug Patent Trial
By Brian Dowling · November 9, 2022, 6:59 PM EST
A Boston federal jury on Wednesday ordered Eli Lilly & Co. to pay $176.5 million to Teva Pharmaceuticals after finding that its migraine drug Emgality willfully infringed three Teva patents....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login